

## CMBI Credit Commentary - JIAYUA

### JIAYUA: Solid results met expectations

Jiayuan reported solid interim results, in line with our previous expectations. Company improved its balance sheet and maintained good profitability, thanks to asset injections funded by equity and equity-like CBs. Jiayuan remained in green camp under “3-red-line” policy, and replaced good size of nonstandard borrowings with bank loans. **With JIAYUAs trading at 13.5% to 14.5%, we maintain our OW recommendation, credit to its continuous improving story, lower beta performance, active debts management, potential equity or equity related financing, and upside pressure of its credit ratings.**

**All-round improvement in interim results.** Jiayuan delivered revenue of RMB9.4bn (+9% vs. 1H20 before restatement). Gross margin normalized to 32% (2020: 32%; 1H20: 37%). EBITDA slightly declined 6% to RMB2.7bn. Profits rose 35% thanks to gains from non-cash items. NCI as of total profits is 10%.

On its balance sheet, Jiayuan further improved “3-red-line” metrics with net gearing of 41% (2020: 60%), adj. lia-to-asset of 62% (2020: 67%) and cash/ST debts ratios of 1.5x (2020: 1.5x), albeit total debts grew RMB1.5bn to RMB22.9bn. Debt profile notably improved as non-standard borrowings lowered to 13% (2020: 23%) and bank borrowings portion rose to 43% (2020: 33%). Contract liabilities increased 9% to RMB20.7bn, which covers 1.1x of its full year revenue target.

Operational wise, Jiayuan achieved RMB19.1bn pre-sales (+64% yoy, 47% completion rate), with 81% attributable and 80% cash collection rate. Company spent RMB6bn in land acquisition for 7 projects, adding 1.1mn sqm GFA at average land cost of RMB5.2k per sqm (40% of 1H21 presale’s ASP). Management guided to use 40% of sales collection for land acquisitions for 2021FY.

**Sufficient and cheap land bank driven by asset injection.** On 30 Jun, 2021, the Shandong asset injection from the controlling shareholder was completed. The Shandong assets are 3 projects in Qingdao including an urban redevelopment project and 1 in Weihai. The total GFA of these projects is 1.62mn sqm and asset size is RMB30bn (NAV RMB6.8bn). As per the company, the Shandong assets (3 in Qingdao including an urban redevelopment project and 1 in Weihai) will have a GPM of 37%.

**Wilson Lu 路伟同**

(852) 3761 8918

wilsonlu@cmbi.com.hk

**Glenn Ko, CFA 高志和**

(852) 3657 6235

glennko@cmbi.com.hk

**Polly Ng 吴宝玲**

(852) 3657 6234

pollyng@cmbi.com.hk

**James Wen 温展俊**

(852) 3757 6291

jameswen@cmbi.com.hk

**CMBI Fixed Income**

fis@cmbi.com.hk

As of 1H21, Jiayuan owns 15.6mn sqm unsold land bank with saleable value of RMB210bn and an attributable ratio of 83%, covering 5x of 2021's pre-sales target. Average land costs were RMB2.5k per sqm, translating into 19% of the ASP sold 1H21 (~RMB13k per sqm).

**Active debt management.** In 2021, Jiayuan engaged in active debt management and improved its maturity profile. Company tendered USD117mn bonds puttable in 2021, USD12mn bonds due in 2022, and USD80mn bonds due in 2023. It also repurchased USD5mn 23s and USD3mn 24s bonds through secondary market.

On the issuance side, Jiayuan issued USD300mn notes due in 2023 and USD130mn notes due in 2024 and USD. In addition, Jiayuan issued USD100mn CBs which will mature in 3.5 years and puttable in 2.5 years. In our view, the CBs issuance is credit positive and the CBs are equity-like because: 1) CBs is structured to make conversion into equity; 2) we expect to see more equity and equity-related financing after the lock-up period, since more dilution is needed for the chairman to fully convert his CBs. The CBs and potential equity financing will notably enlarge Jiayuan's equity base.

**Potential positive credit rating action.** Taking cue from further improved credit metrics, lower reliance on nonbank borrowings, and successful offshore debts management, we access Jiayuan's credit ratings (B stable/B2 stable/B stable positive by S&P/Moody's/Fitch) has improved to be within the thresholds of the upside credit rating scenarios indicated by rating agencies. We expect Jiayuan's adj. debt/EBITDA to below 3.5x (S&P's requires below 4.0x for upgrade) and revenue/EBIT to above 80% (Moody's requires to above 70% for upgrade), as of 1H21. Having that said, the credit rating actions are still subject to company's negotiation with rating agencies, under bearish market sentiment especially on developers.

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

### Disclaimer

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap.

**27 Aug 2021**

---

289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.